peptide receptor radionuclide therapy

You have access
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
Michael Gabriel, Bernhard Nilica, Bernhard Kaiser and Irene J. Virgolini

Journal of Nuclear Medicine April 1, 2019, 60 (4) 524-529; DOI: https://doi.org/10.2967/jnumed.118.215376
You have access
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Karin Niepsch, Dirk Müller and Richard P. Baum

Journal of Nuclear Medicine March 1, 2019, 60 (3) 377-385; DOI: https://doi.org/10.2967/jnumed.118.215848
You have access
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Alexander W. Sauter, Rosalba Mansi, Ulrich Hassiepen, Lionel Muller, Tania Panigada, Stefan Wiehr, Anna-Maria Wild, Susanne Geistlich, Martin Béhé, Christof Rottenburger, Damian Wild and Melpomeni Fani

Journal of Nuclear Medicine March 1, 2019, 60 (3) 393-399; DOI: https://doi.org/10.2967/jnumed.118.207845
You have access
Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine
Caroline Martini, Sabine Buxbaum, Margarida Rodrigues, Bernhard Nilica, Lorenza Scarpa, Bernhard Holzner, Irene Virgolini and Eva-Maria Gamper

Journal of Nuclear Medicine October 1, 2018, 59 (10) 1566-1573; DOI: https://doi.org/10.2967/jnumed.117.204834
You have access
SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework
Rudolf A. Werner, Lilja B. Solnes, Mehrbod S. Javadi, Alexander Weich, Michael A. Gorin, Kenneth J. Pienta, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe and Constantin Lapa

Journal of Nuclear Medicine July 1, 2018, 59 (7) 1085-1091; DOI: https://doi.org/10.2967/jnumed.117.206631
You have access
Somatostatin Receptor 2–Targeting Compounds
Daan A. Smit Duijzentkunst, Dik J. Kwekkeboom and Lisa Bodei

Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 54S-60S; DOI: https://doi.org/10.2967/jnumed.117.191015
You have access
Somatostatin Receptor Antagonists for Imaging and Therapy
Melpomeni Fani, Guillaume P. Nicolas and Damian Wild

Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 61S-66S; DOI: https://doi.org/10.2967/jnumed.116.186783
You have access
NAMPT Inhibitor GMX1778 Enhances the Efficacy of ¹⁷⁷Lu-DOTATATE Treatment of Neuroendocrine Tumors
Anna-Karin Elf, Peter Bernhardt, Tobias Hofving, Yvonne Arvidsson, Eva Forssell-Aronsson, Bo Wängberg, Ola Nilsson and Viktor Johanson

Journal of Nuclear Medicine February 1, 2017, 58 (2) 288-292; DOI: https://doi.org/10.2967/jnumed.116.177584
You have access
⁹⁰Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas
Karine Gerster-Gilliéron, Flavio Forrer, Helmut Maecke, Jan Mueller-Brand, Adrian Merlo and Dominik Cordier

Journal of Nuclear Medicine November 1, 2015, 56 (11) 1748-1751; DOI: https://doi.org/10.2967/jnumed.115.155853
You have access
Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate
Samer Ezziddin, Mared Attassi, Charlotte J. Yong-Hing, Hojjat Ahmadzadehfar, Winfried Willinek, Frank Grünwald, Stefan Guhlke, Hans-Jürgen Biersack and Amir Sabet

Journal of Nuclear Medicine February 1, 2014, 55 (2) 183-190; DOI: https://doi.org/10.2967/jnumed.113.125336

Main menu

User menu

Search

peptide receptor radionuclide therapy

Pages